Please login to the form below

Not currently logged in
Email:
Password:

Ixempra

This page shows the latest Ixempra news and features for those working in and with pharma, biotech and healthcare.

Bayer fails to overturn Nexavar compulsory licence in India

Bayer fails to overturn Nexavar compulsory licence in India

drugs. There have already been suggestions that Roche's breast cancer treatment Herceptin (trastuzumab) and Bristol-Myers Squibb's leukaemia medicine Sprycel (dasatinib) and chemotherapy Ixempra (ixabepilone) could follow Nexavar down

Latest news

  • India could hit Roche and BMS with compulsory licences India could hit Roche and BMS with compulsory licences

    Generic versions of Herceptin, Sprycel and Ixempra may reach market before patent expiration. ... According to the Indian Express, Herceptin, Ixempra and Sprycel cost 50, 000 rupees (687), 70, 000-80, 000 rupees (961 to 1, 098) and 15, 000 rupees (206)

  • Eisai wins approval for breast cancer drug

    and with Bristol-Myers Squibb's Ixempra (ixabepilone), which is marketed for patients with late- stage disease after failure of an anthracycline, taxane and Xeloda.

  • Bristol-Myers signs cancer drug deal

    BMS' existing cancer-drug portfolio includes Erbitux (cetuximab), Ixempra (ixabepilone) and Sprycel (dasatinib).

  • FDA approves BMS chemotherapy drug

    Ixempra was approved for use in women who have failed treatment on three other types of chemotherapy. ... Ixempra inhibits the protein tubulin, which stops cells growing and dividing by arresting the cell cycle.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics